SOLICITATION NOTICE
B -- Cancer Following Bone Marro Transplantation: Study Extension
- Notice Date
- 7/26/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- Reference-Number-NCI-20088-NV
- Response Due
- 8/12/2002
- Point of Contact
- Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - David Keefer, Contracting Officer, Phone (301) 435-3801, Fax (301) 480-0309,
- E-Mail Address
-
dm170b@nih.gov, dk63h@nih.gov
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics, Radiation Epidemilogy Branch (REB) plans to enter into a sole source contract with Dr. Catherine Metayer, Calistoga, CA 94515. This procurement will provide expert epidemiological and statistical analyses of data on a REB case-control study entitled ?Second Cancers Following Allogeneic Bone Marrow Transplantation (BMT) Study. The Radiation Epidemiology Branch is collaborating with the Fred Hutchinson Cancer Research Center (FHCRC) and the Medical College of Wisconsin, the statistical center for the International Bone Marrow Transplant Registry (IBMTR-over 300 transplant centers world wide) to evaluate the risk of new malignancy among 26,000 BMT recipients. This study has focused primarily on the risk of solid tumors developing among long-term survivors, and post-transplanted lymphoproliferative disorders (PTLD) developing early in the follow-up period. Previous analyses done with the assistance of Dr. Metayer (263-MQ-115854) have opened up new areas for statistical exploration and additional analyses is needed. The goals of the study are to quantify the risk of secondary solid cancer, overall and by individual anatomic site, and for post-transplant lymphoproliferative disorders according to: 1) pre-transplant conventional chemotherapy and radiotherapy; 2) preparative regimens for transplant, such as total body irradiation and intensive radiation, and 3) duration and drug type of immunosuppressive therapy for post-transplant graft-verus-host disease (GVHD) and post transplant disease-specific therapy. Using datasets supplied by NCI, the Dr. Metayer will assist NCI in performing data analysis, epidemiologic evaluation, and data editing of the completed case-control studies into new areas identified by the previous analyses. The vendor will further explore 2nd cancer risks associated with specific drug treatments to evaluate potential statistical interactions with age, geographic region and other potential confounders. Data editing will be required to prepare the drug data for analysis. Conditional logistic regression analyses for matched case-control studies will be used, and statistical methods to identify interactions in these data will be employed. In addition, for this study extension, unconditional logistic regression will be needed. As before, all analyses will be performed for solid tumors, overall and at each anatomical site, and for PTLDs. Dr. Catherine Metayer, a physician and a PhD trained medical epidemiologist, is uniquely qualified to conduct the epidemiologic and statistical analyses in the REB studies on bone marrow transplantation. She is the only scientist collaborating on the Second Cancers Following Allogeneic BMT Study (Allo BMT) with the required training in medicine, epidemiology of treatment-induced neoplasms, and expertise in statistical methodology for matched case-control designs. Dr. Catherine Metayer?s experience is unique in that she participated in the design and implementation of the Allo BMT study and has conducted the initial phase of the data analyses. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI research to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 12, 2002. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect call will be accepted.
- Record
- SN00126179-W 20020728/020726213230 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |